Overcoming cellular senescence in human cancer pathogenesis

Genes and Development

Volumn 12, Issue 2, 1998, Pages 163-174

  Yeager, Thomas R ^a,c   DeVries, Sandy ^g   Jarrard, David F ^a,b   Kao, Chinghai ^f   Nakada, Stephen Y ^a,b   Moon, Timothy D ^a,b   Bruskewitz, Reginald ^a,b   Stadler, Walter M ^e   Meisner, Lorraine F ^d   Gilchrist, Kennedy W ^a,b   Newton, Michael A ^a   Waldman, Frederic M ^g   Reznikoff, Catherine A ^a,b,c  

^a Department of Human Oncology ^*  (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c Cell and Molecular Biology Program   (United States)

^d WISCONSIN STATE LABORATORY OF HYGIENE   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

+20; 3p; 8p; Cancer progression; p16; p53; pRb; Senescence

Indexed keywords

PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ARTICLE; BLADDER CANCER; CARCINOGENESIS; CELL AGING; CELL IMMORTALIZATION; CHROMOSOME ABERRATION; CHROMOSOME LOSS; CONTROLLED STUDY; DNA HYBRIDIZATION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; KARYOTYPE; MALE; PRIORITY JOURNAL; STATISTICAL MODEL; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE; UROTHELIUM;

EID: 15444339879     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.12.2.163     Document Type: Article

References (50)

1. American Cancer Society. 1997. Cancer facts and figures-1996, 96-300M-No. 5008.96. American Cancer Society, Bethesda, MD.
2. Balazs, M., P. Carroll, R. Kerschmann, S. Sauter, and F.M. Waldman. 1997. Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization. Genes, Chrom. Cancer 19: 84-89.
3. Bane, B.L., J.Y. Rao, and G.P. Hemstreet. 1996. Pathology and staging of bladder cancer. Semin. Oncol. 23: 546-570.
4. Belair, C.D., T.R. Yeager, P.M. Lopez, and C.A. Reznikoff. 1997. Telomerase activity: A biomarker for proliferation - not malignant transformation. Proc. Natl. Acad. Sci. (in press).
5. Cairns, P., L. Mao, A. Merlo, D.J. Lee, D. Schwab, Y. Eby, K. Tokino, P. van der Reit, J.E. Blaugrund, and D. Sidransky. 1994. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265: 415-416.
6. Cairns, P., T.J. Polascik, Y. Eby, K. Tokino, J. Califorino, A. Merlo, L. Mao, J. Hearath, R. Jenkins, W. Westra, J.L. Rutter, A. Bukler, E. Gabrielson, M. Tockman, K.R. Cho, L. Hendrick, G.S. Bova, W. Isaacs, W. Koch, D. Schwab, and D. Sidransky. 1995. Frequency of homozygous deletion at p16/ CDKN2 in primary human tumors. Nature Genet. 11: 210-212.
7. Catalona, W.J. 1992. Urothelial tumors of the urinary tract. In Campbell's Urology (ed. P.C. Walsh, A.B. Retik, T.A. Stamey, and E.D. Vaughn), Chapter 28, pp. 1094-1158. W.B. Sanders, Philadelphia, PA.
8. Cordon-Cardo, C., Z.-F. Zhang, G. Dalbangi, M. Drobnjak, E. Charytonowicz, S.-X. Hu, H.-J. Xu, V.E. Reuter, and W.F. Benedict. 1997. Cooperative effects of p53 and pRb alteration in primary superficial bladder tumors. Cancer Res. 57: 1217-1221.
9. Dimri, G.P. and J. Campisi. 1994. Molecular and cellular biology of replicative senescence. Cold Spring Harbor Symp. Quant. Biol. 59: 67-73.
10. Dimri, G.P., X. Lee, G. Basile, M. Ascota, G. Scott, C. Roskelley, E.E. Medranos, L. Linskens, O. Peoria-Smith, M. Peacocke, and J. Campisi. 1995. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. 92: 9363-9367.
11. Efron, B. and R. Tibshirani. 1993. An introduction to the bootstrap. Chapman and Hall, London, UK.
12. Esrig, D., D. Elmnain, S. Groshen, J.A. Freeman, J.P. Stein, S.-C. Chen, P.W. Nichols, D.G. Skinner, P.A. Jones, and R.J. Cote. 1994. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med. 331: 1259-1264.
13. Gonzalez-Zulueta, M., C.H. Bender, A.S. Yang, T. Nguyen, R.W. Beart, J.M. Van Tornout, and P.A. Jones. 1995. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 55:4531-4535.
14. Harley, C.B. 1995. Telomeres and aging. In Telomeres (ed. E.H. Blackburn and C.W Greider), pp. 247-263. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
15. Hayflick, L. 1974. The longevity of cultured human cells. Assoc. Am. Geriatr. Soc. 22L: 1-12.
16. Hollstein, M., D. Sidransky, B. Vogelstein, and C.C. Harris. 1991. p53 mutations in human cancers. Science 253: 49-53.
17. Hubuchi, T., O. Ogawa, Y. Kakehi, K. Ogura, M. Koshiba, S. Hamazaki, R. Takahashi, T. Sugiyama, and O. Yoshida. 1993. Accumulated allelic losses in the development of urothelial cancer. Int. J. Cancer 53: 579-584.
18. Kallioniemi, A., O.-P. Kallioniemi, G. Citro, G. Sauter, S. DeVries, R. Kerschmann, P. Caroll, and F. Waldman. 1995. Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization. Genes, Chrom. Cancer 12: 213-219.
19. Kamb, A., N.A. Gruis, J. Weaver-Feldhaus, Q. Lui, K. Harshman, S.V. Tavigian, E. Stoker, R. S. Day, B.E. Johnson, and M.H. Skolnik. 1994. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 463-440.
20. Kannio, A., M. Ridanpaa, H. Koskinen, T. Partanen, S. Anttila, Y. Collan, E. Hietanen, H. Vainio, and K. Husgafvel-Pursiainen. 1996. A molecular and epidemiological study on bladder cancer: p53 mutations, tobacco smoking and occupational exposure to asbestos. Cancer Epidemiol. Biomarkers Prev. 5:33-39.
21. Knowles, M.A., P.A. Elder, M. Williamson, J.P. Cairns, M.E. Shaw, and M.G Law. 1994. Allelotype of human bladder cancer. Cancer Res. 54: 531-538.
22. Lowe, S.W. and T. Jacks. 1997. Response to a letter. Nature 385: 124-125.
23. Lukas, J., D. Perry, L. Aagaard, D.J. Mann, A. Bartokva, M. Strauss, G. Peters, and J. Bartek. 1995. Retinoblastoma-protein-dependent cell cycle inhibition by the tumor suppressor p16. Nature 375: 503-506.
24. Medema, R.H., R.E. Merrera, F. Lam, and R.A. Weinberg. 1995. Growth suppression by p16ink4 requires functional retinoblastoma protein. Proc. Natl. Acad. Sci. 92: 6289-6293.
25. Merlo, A., J.G. Herman, L. Mao, D.J. Lee, E. Gabrielson, P.C. Burger, S.B. Baylin, and D. Sidransky. 1995. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nature Med. 1: 686-692.
26. Mertens, F., B. Johansson, M. Hoglund, and F. Mitelman. 1997. Chromosome imbalance maps of malignant solid tumors: A cytologic survey of 3185 neoplasims. Cancer Res. 57: 2765-2780.
27. Meyerson, M., C.M. Counter, E.N. Eaton, L.W. Ellisen, P. Steiner, S.D. Caddle, L. Ziaugra, R.L. Beijersbergen, M.J. Davidoff, Q. Liu, S. Bacchetti, D.A. Haber, and R.A. Weinberg. 1997. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90: 785-795.
28. Newton, M.A., S.Q. Wu, and C.A. Reznikoff. 1994. Assessing the significance of chromosome-loss data: Where are the suppressor genes for bladder cancer? Stat. Med. 13: 839-858.
29. Nseyo, U.O. and D.L. Lamm. 1996. Therapy of superficial bladder cancer. Semin. Oncol. 23: 598-604.
30. Ohta, K., M. Kuwahara, N. Fujisaki, S. Kagawa, M. Fuihata, and Y. Ohtsuki. 1997. Overexpressed cyclin D1 protein related to p53 and retinoblastoma proteins in translational cell carcinoma of the urinary tract. Oncology Rep. 4: 97-101.
31. Okajima, J., T. Fukuda, S. Okita, M.Tsutsumi, Y. Hirao, and Y. Konishi. 1996. Infrequent somatic alteration of p16/MTS1 in human primary superficial bladder cancers. Cancer Lett. 103:227-231.
32. Presti, J.C., V.E. Reuter, T. Galan, W.R. Fair, and C. Cordon-Cordo. 1991. Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res. 51: 5405-5409.
33. Reznikoff, C.A., K.W. Gilchrist, D.H. Norback, K.B. Cummings, E. Erturk, and G.T. Bryan. 1983. Altered growth patterns in vitro of human papillary transitional carcinoma cells. Am. J. Pathol. 111: 263-272.
34. Reznikoff, C.A., L.J. Loretz, D.M. Presciotta, T.D. Oberley, and M.M. Ignatovic. 1987. Growth kinetics and differentiation in vitro of normal human uroepithelial cells on collagen gel substrates in defined medium. J. Cell Physiol. 131: 285-301.
35. Reznikoff, C.A., C. Belair, E. Savelieva, Y. Zhai, K. Pfeifer, T. Yeager, K.J. Thompson, S. DeVries, C. Bindley, M.A. Newton, G. Sekhon, and F. Waldman. 1994. Long-term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7-, but not E6-, immortalized human uroepithelial cells. Genes & Dev. 8: 2227-2240.
36. Reznikoff, C.A., C.D. Belair, T.R. Yeagei, E. Savelieva, R.H. Blelloch, J.A. Puthenveettil, and S. Cuthill. 1996a. A molecular genetic model of human bladder cancer pathogenesis. Semin. Oncol. 23: 571-584.
37. Reznikoff, C.A., T.R. Yeager, C.D. Belair, E. Savelieva, J.A. Puthenveettil, and W.M. Stadler. 1996b. Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human urothelial cells. Cancer Res. 56: 2886-2890.
38. Ross, K., P.A. Jones, and M.C. Yu. 1996. Bladder cancer epidemiology and pathogenesis. Semin. Oncol. 23: 536-545.
39. Sarkis, A.S., G. Dalbagni, C. Cordon-Cordo, Z-F. Zhang, J. Sheinfeld, W.F. Fair, H.W. Herr, and V.E. Reuter. 1993. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression. J. Natl. Cancer Inst. 85: 53-59.
40. Savelieva, E., C.D. Belair, M.A. Newton, S. DeVries, J.W. Gray, F. Waldman, and C.A. Reznikoff. 1997. 20q gain associates with immortalization: 20q13.2 amplification correlates with genome instability in human papillomavirus 16 E7 transformed human uroepithelial cells. Oncogene 14: 551-560.
41. Serrano, M., G.J. Hannon, and D. Beach. 1993. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707.
42. Serrano, M., A.W. Lin, M.E. McCurrach, D. Beach, and S.W. Lowe. 1997, Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16ink4a. Cell 88: 593-602.
43. Shin, K.Y., G. Kong, W.S. Kim, T.Y. Lee, Y.N. Woo, and J.D. Lee. 1997. Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers. Br. J. Cancer 75: 1788-1792.
44. Soder, A.I, S.F. Hoare, S. Muir, J.J. Going, E.K. Parkinson, and W.N. Keither. 1997. Amplification, increased dosage and in situ expression of the telomerase gene in human cancer. Oncogene 14: 1013-1021.
45. Spruck, C.H., P.F. Ohneseit, M. Gonzalez-Zuleta, D. Esrig, N. Miyao, Y.C. Tsai, S.P. Lerner, C. Schmutte, A.S. Yang, R. Cote, L. Dubeau, P.W. Nichols, G.G. Hermann, K. Steven, T. Horn, D.G. Skinner, and P.A. Jones. 1994a. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 54: 784-788.
46. Spruck, C.H., M. Gonzalez-Zulueta, A. Shibata, A. Simoneau, M-F. Lin, F. Gonzales, Y.C. Tsai, and P.A. Jones. 1994b. p16 gene in uncultured tumors. Nature 370: 183-184.
47. Takle, L.A. and M.A. Knowles. 1996. Deletion mapping implicates two tumor suppressor genes on chromosome 8p in the development of bladder cancer. Oncogene 12: 1083-1087.
48. Vieten, L., C.D. Belair, L. Savelieva, K. Julicher, F. Broker, W. Bardenheuer, and J. Schuttee. 1997. Minimal deletion of 3p13 → p14.2 associated with immortalization of human uroepithelial cells. Genes, Chrom. Cancer (in press).
49. Xu, H.-J., P. Cairns, S.-X. Hu, M.A. Knowles, and W.F. Benedict. 1993. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. Int. J. Cancer 53: 781-784.
50. Yeager, T., W. Stadler, C. Belair, J. Puthenveettil, O. Olopade, and C. Reznikoff. 1995. Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res. 55: 493-497.